The 2 Wall Street analysts covering Filana Therapeutics, Inc. hold a median 12-month price target of $6.5 — +844.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 66 of 100 as at 19 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Filana Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (86): Sales and profits are climbing, and climbing faster than before.
Value (22): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on FLNA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +844.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 26 May 2026 | Maxim Group | Reinstates | Buy | $5.00 |
| 6 Oct 2025 | LUCID CAPITAL MARKETS | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
FLNA appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Oct 2026, Filana Therapeutics, Inc. returned −84.4% against +15.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 80% of US stocks
Cheaper than 82% of US stocks
Cheaper than 55% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 20% of US stocks
Higher than 29% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Filana Therapeutics, Inc. has a market value of $32.8M and an enterprise value of −$49.7M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$42.3M.
Diluted earnings per share, trailing twelve months: $−0.87.
Free cash flow in the twelve months to 30 June 2026: −$29.3M.
Trailing P/E: −0.4×; forward P/E: −0.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Filana Therapeutics, Inc. employs 17 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Filana Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Filana Therapeutics announced that its management team will participate in the 2026 Maxim Growth Summit, scheduled for October 12–14, 2026, in New York.
Why it matters — The announcement informs FLNA watchers of an upcoming event involving the company's management team.
The U.S. Food and Drug Administration removed a clinical hold on the investigational new drug application for Filana Therapeutics, Inc. (NASDAQ:FLNA), a decision announced on Tuesday that advances the company's epilepsy research forward.
Why it matters — A FLNA watcher would care because lifting the clinical hold clears a regulatory barrier and allows Filana's epilepsy research program to move ahead.
The FDA lifted the clinical hold on Filana Therapeutics' investigational new drug application for simufilam, clearing the way for the company to initiate a planned Phase 2a proof-of-concept study in patients aged 12 to 55 with TSC-related epilepsy. Patient screening for the study is expected to begin by the first quarter of 2027, with a clinical research organization engaged, trial sites identified, and investigators being recruited.
Why it matters — The FDA's lift of the clinical hold removes a regulatory barrier and enables Filana to move its lead candidate, simufilam, into the next clinical development stage for TSC-related epilepsy.
A law firm is encouraging Filana Therapeutics, Inc. shareholders to contact them to discuss their rights and options regarding potential breaches of fiduciary duties by company insiders. The firm states it would handle any matter on a contingent fee basis, with no out-of-pocket legal fees for shareholders.
Why it matters — FLNA watchers may note that insiders are being investigated over potential fiduciary duty breaches to shareholders.
Filana Therapeutics, Inc. reported its financial results for the second quarter ended June 30, 2026, and provided a business update. The company currently focuses on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy.
Why it matters — This is a regular quarterly update that gives FLNA watchers a look at the company's financial performance and the status of its pipeline in TSC-related epilepsy.
The 2 Wall Street analysts covering Filana Therapeutics, Inc. have a median 12-month price target of $6.5, with estimates ranging from $5 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Filana Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Filana Therapeutics, Inc. 66 out of 100 across roughly 4,600 US stocks as at 19 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 19 Oct 2026, Filana Therapeutics, Inc. ranks 66 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (86 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +844.1% from the last close, and Ticker Nerd's factor model ranks Filana Therapeutics, Inc. 66 out of 100 as at 19 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Filana Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FLNA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $8 over the next 12 months.
Filana Therapeutics, Inc. returned -84.4% over the 12 months to 20 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Filana Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing investigational therapies for central nervous system disorders.
The most recent item we track (GlobeNewsWire, 9 Oct 2026): "Filana Therapeutics to Participate in the 2026 Maxim Growth Summit". Filana Therapeutics announced that its management team will participate in the 2026 Maxim Growth Summit, scheduled for October 12–14, 2026, in New York.
Filana Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing investigational therapies for central nervous system disorders. The company’s current work centers on simufilam, an oral small-molecule candidate being studied for TSC-related epilepsy and other neurological conditions linked to filamin A, along with SavaDx, an early-stage blood-based diagnostic program designed to detect Alzheimer’s disease. Based in Austin, Texas, Filana Therapeutics operates in the biotechnology sector with a research-driven model built around drug development and biomarker discovery. Its programs target complex brain disorders where new treatment and diagnostic options remain limited, positioning the company as a specialized participant in the neuroscience and precision-medicine landscape.
CEO Mr. Richard Jon Barry · 17 employees · United States · https://www.filanatx.com
